BELITE BIO INC - AMER

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

05 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

03 11 2024 16:00:27 提供 Nasdaq GlobeNewswire

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

14 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

08 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

10 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio to Participate in Three Upcoming Investor Conferences

03 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

01 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

09 8 2024 16:30:00 提供 Nasdaq GlobeNewswire

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

08 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

05 8 2024 19:10:54 提供 Nasdaq GlobeNewswire

Belite Bio to Present at the JonesHealthcare Seaside Summit

08 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

12 6 2024 02:55:28 提供 Nasdaq GlobeNewswire

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference

14 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

13 5 2024 21:50:29 提供 Nasdaq GlobeNewswire

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

08 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

06 5 2024 08:15:00 提供 Nasdaq GlobeNewswire

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

06 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

01 5 2024 16:15:00 提供 Nasdaq GlobeNewswire

Belite Bio Announces $25 Million Registered Direct Offering

25 4 2024 19:15:29 提供 Nasdaq GlobeNewswire